Posts Tagged ‘type 2 diabetes’

Semaglutide in Patients with Type 2 Diabetes

Posted by • November 10th, 2016

Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The preapproval Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) conducted by Marso et al. was designed to assess… Read More…

Adalimumab in Patients with Active Non-Infectious Uveitis

Posted by • September 8th, 2016

A 44-year-old woman with type 2 diabetes mellitus and sarcoidosis presents with a 3-week history of severe visual disturbance in both eyes. After referral to an ophthalmologist, she is diagnosed with idiopathic posterior uveitis. Her symptoms improved while receiving oral steroids over the course of 5 months. However, after completing steroid treatment, her glycemic control… Read More…

Liraglutide in Type 2 Diabetes

Posted by • July 28th, 2016

To assess the long-term effects of liraglutide on cardiovascular outcomes and other clinically important events, the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial was initiated in 2010. Patients with type 2 diabetes who had a glycated hemoglobin level of 7.0% or more were eligible if they either had not… Read More…

Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes

Posted by • October 10th, 2014

In a follow-up study of patients with type 2 diabetes, mortality benefits in those originally assigned to antihypertensive therapy were evident at the end of follow-up, but in-trial glucose differences did not result in long-term benefits in mortality or macrovascular events. Post-trial follow-up studies of patients with diabetes have previously reported long-term beneficial effects of earlier… Read More…

After the STAMPEDE: Surgical versus Medical Treatment for Obese Patients with Diabetes

Posted by • May 21st, 2014

Today the perils of obesity hardly remain a mystery.  Many patients who are obese also have Type 2 diabetes, a condition that can be difficult and expensive to manage, and the search for effective treatment options has become a public health priority. In 2012, an article in NEJM reported the results of the Surgical Treatment and… Read More…

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

Posted by • December 26th, 2013

Intuitively, controlling diabetic kidney disease should be easy – manage hyperglycemia, manage blood pressure. And the more control, the better, right? Unfortunately, it hasn’t been so simple. With effective treatment of hyperglycemia and control of blood pressure, the incidence of end-stage renal disease (ESRD) due to diabetes has reached a plateau in the past 10 years. But… Read More…

New Clinical Decisions: Controlling Type 2 Diabetes

Posted by • October 3rd, 2013

Which drug is best for a patient who needs to get her glycated hemoglobin level down to 7.0%? Review the arguments, choose a treatment option, and share your comments in our latest Clinical Decisions. Agnes is a 51-year-old widow with hypertension who has not been able to gain complete control over her type 2 diabetes since being… Read More…

Insulin and Cardiovascular Outcomes in Dysglycemia

Posted by • July 27th, 2012

In a new study from the ORIGIN Trial Investigators with a 2-by-2 factorial design, patients with cardiovascular risk factors and dysglycemia or type 2 diabetes received insulin glargine or standard care. Insulin treatment did not affect cardiovascular events, the primary outcome. An elevated fasting plasma glucose level is an independent risk factor for adverse cardiovascular outcomes. Basal… Read More…

Therapy in Youth with Type 2 Diabetes

Posted by • June 13th, 2012

Just twenty years ago only 3 of 100 adolescents with diabetes had Type 2 diabetes (T2DM); today that proportion nears 1 in 2. Moreover, this epidemic of T2DM disproportionately affects disadvantaged children, many of whom grow up in environments that lack healthy food options or safe exercise facilities. Though it is clearly urgent to devise medical, behavioral,… Read More…

Medical Therapy vs. Bariatric Surgery in Type 2 Diabetes

Posted by • April 27th, 2012

In the 91 years since the discovery of insulin therapy for diabetes by Banting and Best in 1921, the prevalence of type 1 and especially type 2 diabetes has skyrocketed, tied to the ongoing epidemic of obesity. With the global prevalence of type 2 diabetes now expected to hit nearly 10 percent of the world’s population… Read More…